Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
sturge weber syndrome market

SALE

Sturge-weber Syndrome (SWS) - Market Insight, Epidemiology And Market Forecast - 2032

Published Date : 2023

Pages : 200

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
Companies
- Sample Request

Sturge-weber Syndrome Market

DelveInsight's "Sturge-weber Syndrome (SWS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sturge-weber Syndrome (SWS), historical and forecasted epidemiology as well as the Sturge-weber Syndrome (SWS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Sturge-weber Syndrome (SWS) market report provides current treatment practices, emerging drugs, Sturge-weber Syndrome (SWS) market share of the individual therapies, current and forecasted Sturge-weber Syndrome (SWS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Sturge-weber Syndrome (SWS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Sturge-weber Syndrome (SWS) market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Sturge-weber Syndrome (SWS) Disease Understanding and Treatment Algorithm

The DelveInsight’s Sturge-weber Syndrome (SWS) market report gives a thorough understanding of the Sturge-weber Syndrome (SWS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Sturge-weber Syndrome (SWS) Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Sturge-weber Syndrome (SWS).

Sturge-weber Syndrome (SWS) Treatment

It covers the details of conventional and current medical therapies available in the Sturge-weber Syndrome (SWS) market for the treatment of the condition. It also provides Sturge-weber Syndrome (SWS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Sturge-weber Syndrome (SWS) Epidemiology

The Sturge-weber Syndrome (SWS) epidemiology section provides insights about the historical and current Sturge-weber Syndrome (SWS) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Sturge-weber Syndrome (SWS) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Sturge-weber Syndrome (SWS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Sturge-weber Syndrome (SWS) Epidemiology

The epidemiology segment also provides the Sturge-weber Syndrome (SWS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Sturge-weber Syndrome (SWS) Drug Chapters

The drug chapter segment of the Sturge-weber Syndrome (SWS) report encloses the detailed analysis of Sturge-weber Syndrome (SWS) marketed drugs and late-stage (Phase-III and Phase-II) Sturge-weber Syndrome (SWS) pipeline drugs. It also helps to understand the Sturge-weber Syndrome (SWS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Sturge-weber Syndrome (SWS) Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Sturge-weber Syndrome (SWS) treatment.

Sturge-weber Syndrome (SWS) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Sturge-weber Syndrome (SWS) treatment.

Sturge-weber Syndrome (SWS) Market Outlook

The Sturge-weber Syndrome (SWS) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Sturge-weber Syndrome (SWS) market trends by analyzing the impact of current Sturge-weber Syndrome (SWS) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Sturge-weber Syndrome (SWS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sturge-weber Syndrome (SWS) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Sturge-weber Syndrome (SWS) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Sturge-weber Syndrome (SWS) market in 7MM.

The United States Market Outlook

This section provides the total Sturge-weber Syndrome (SWS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Sturge-weber Syndrome (SWS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Sturge-weber Syndrome (SWS) market size and market size by therapies in Japan is also mentioned.

Sturge-weber Syndrome (SWS) Drugs Uptake

This section focuses on the rate of uptake of the potential Sturge-weber Syndrome (SWS) drugs recently launched in the Sturge-weber Syndrome (SWS) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Sturge-weber Syndrome (SWS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

Sturge-weber Syndrome (SWS) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Sturge-weber Syndrome (SWS) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sturge-weber Syndrome (SWS) Pipeline Development Activities

The Sturge-weber Syndrome (SWS) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Sturge-weber Syndrome (SWS) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Sturge-weber Syndrome (SWS) report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Sturge-weber Syndrome (SWS) emerging therapies.

Reimbursement Scenario in Sturge-weber Syndrome (SWS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Sturge-weber Syndrome (SWS) market trends, we take KOLs and SMEs ' opinion working in the Sturge-weber Syndrome (SWS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Sturge-weber Syndrome (SWS) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Sturge-weber Syndrome (SWS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Sturge-weber Syndrome (SWS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Sturge-weber Syndrome (SWS) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Sturge-weber Syndrome (SWS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Sturge-weber Syndrome (SWS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sturge-weber Syndrome (SWS) market

Report Highlights

In the coming years, the Sturge-weber Syndrome (SWS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Sturge-weber Syndrome (SWS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Sturge-weber Syndrome (SWS). The launch of emerging therapies will significantly impact the Sturge-weber Syndrome (SWS) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Sturge-weber Syndrome (SWS)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Sturge-weber Syndrome (SWS) Report Insights

Sturge-weber Syndrome (SWS) Patient Population
Therapeutic Approaches
Sturge-weber Syndrome (SWS) Pipeline Analysis
Sturge-weber Syndrome (SWS) Market Size and Trends
Sturge-weber Syndrome (SWS) Market Opportunities
Impact of upcoming Sturge-weber Syndrome (SWS) Therapies

Sturge-weber Syndrome (SWS) Report Key Strengths

11 Years Forecast
7MM Coverage
Sturge-weber Syndrome (SWS) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Sturge-weber Syndrome (SWS) Report Assessment

Current Treatment Practices
Unmet Needs
Sturge-weber Syndrome (SWS) Pipeline Product Profiles
Sturge-weber Syndrome (SWS) Market Attractiveness
Market Drivers and Barriers

Key Questions

Market Insights:

What was the Sturge-weber Syndrome (SWS) drug class share (%) distribution in 2019 and how it would look like in 2032?
What would be the Sturge-weber Syndrome (SWS) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Sturge-weber Syndrome (SWS) market size during the forecast period (2019-2032)?
At what CAGR, the Sturge-weber Syndrome (SWS) market is expected to grow by 7MM during the forecast period (2019-2032)?
What would be the Sturge-weber Syndrome (SWS) market outlook across the 7MM during the forecast period (2019-2032)?
What would be the Sturge-weber Syndrome (SWS) market growth till 2032, and what will be the resultant market Size in the year 2032?
How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of the Sturge-weber Syndrome (SWS)?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Sturge-weber Syndrome (SWS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Sturge-weber Syndrome (SWS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Sturge-weber Syndrome (SWS)?
Out of all 7MM countries, which country would have the highest prevalent population of Sturge-weber Syndrome (SWS) during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Sturge-weber Syndrome (SWS) treatment in addition to the approved therapies?
What are the current treatment guidelines for the treatment of Sturge-weber Syndrome (SWS) in the USA, Europe, and Japan?
What are the Sturge-weber Syndrome (SWS) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Sturge-weber Syndrome (SWS)?
How many therapies are in-development by each company for Sturge-weber Syndrome (SWS) treatment?
How many are emerging therapies in mid-stage, and late stage of development for Sturge-weber Syndrome (SWS) treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Sturge-weber Syndrome (SWS) therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Sturge-weber Syndrome (SWS) and their status?
What are the current challenges faced in drug development?
What are the key designations that have been granted for the emerging therapies for Sturge-weber Syndrome (SWS)?
What are the global historical and forecasted market of Sturge-weber Syndrome (SWS)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Sturge-weber Syndrome (SWS) market
To understand the future market competition in the Sturge-weber Syndrome (SWS) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Sturge-weber Syndrome (SWS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Sturge-weber Syndrome (SWS) market
To understand the future market competition in the Sturge-weber Syndrome (SWS) market

1. Key Insights

2. Executive Summary of Sturge-weber Syndrome (SWS)

3. Competitive Intelligence Analysis for Sturge-weber Syndrome (SWS)

4. Sturge-weber Syndrome (SWS): Market Overview at a Glance

4.1. Sturge-weber Syndrome (SWS) Total Market Share (%) Distribution in 2019

4.2. Sturge-weber Syndrome (SWS) Total Market Share (%) Distribution in 2032

5. Sturge-weber Syndrome (SWS): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Sturge-weber Syndrome (SWS) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Sturge-weber Syndrome (SWS) Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Sturge-weber Syndrome (SWS) Treatment and Management

8.2. Sturge-weber Syndrome (SWS) Treatment Algorithm

9. Sturge-weber Syndrome (SWS) Unmet Needs

10. Key Endpoints of Sturge-weber Syndrome (SWS) Treatment

11. Sturge-weber Syndrome (SWS) Marketed Products

11.1. List of Sturge-weber Syndrome (SWS) Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Sturge-weber Syndrome (SWS) Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Sturge-weber Syndrome (SWS): Seven Major Market Analysis

13.1. Key Findings

13.2. Sturge-weber Syndrome (SWS) Market Size in 7MM

13.3. Sturge-weber Syndrome (SWS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Sturge-weber Syndrome (SWS) Total Market Size in the United States

15.1.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Sturge-weber Syndrome (SWS) Total Market Size in Germany

15.3.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Sturge-weber Syndrome (SWS) Total Market Size in France

15.4.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Sturge-weber Syndrome (SWS) Total Market Size in Italy

15.5.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Sturge-weber Syndrome (SWS) Total Market Size in Spain

15.6.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Sturge-weber Syndrome (SWS) Total Market Size in the United Kingdom

15.7.2. Sturge-weber Syndrome (SWS) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Sturge-weber Syndrome (SWS) Total Market Size in Japan

15.8.3. Sturge-weber Syndrome (SWS) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Sturge-weber Syndrome (SWS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Tables:

List of Table

Table 1: 7MM Sturge-weber Syndrome (SWS) Epidemiology (2019-2032)

Table 2: 7MM Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases (2019-2032)

Table 3: Sturge-weber Syndrome (SWS) Epidemiology in the United States (2019-2032)

Table 4: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Sturge-weber Syndrome (SWS) Epidemiology in Germany (2019-2032)

Table 6: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Sturge-weber Syndrome (SWS) Epidemiology in France (2019-2032)

Table 8: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Sturge-weber Syndrome (SWS) Epidemiology in Italy (2019-2032)

Table 10: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Sturge-weber Syndrome (SWS) Epidemiology in Spain (2019-2032)

Table 12: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Sturge-weber Syndrome (SWS) Epidemiology in the UK (2019-2032)

Table 14: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Sturge-weber Syndrome (SWS) Epidemiology in Japan (2019-2032)

Table 16: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures:

List of Figures

Figure 1: 7MM Sturge-weber Syndrome (SWS) Epidemiology (2019-2032)

Figure 2: 7MM Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases (2019-2032)

Figure 3: Sturge-weber Syndrome (SWS) Epidemiology in the United States (2019-2032)

Figure 4: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Sturge-weber Syndrome (SWS) Epidemiology in Germany (2019-2032)

Figure 6: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Sturge-weber Syndrome (SWS) Epidemiology in France (2019-2032)

Figure 8: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Sturge-weber Syndrome (SWS) Epidemiology in Italy (2019-2032)

Figure 10: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Sturge-weber Syndrome (SWS) Epidemiology in Spain (2019-2032)

Figure 12: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Sturge-weber Syndrome (SWS) Epidemiology in the UK (2019-2032)

Figure 14: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Sturge-weber Syndrome (SWS) Epidemiology in Japan (2019-2032)

Figure 16: Sturge-weber Syndrome (SWS) Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

Frequently Asked Questions

What is Sturge-weber Syndrome?

Sturge-Weber syndrome (SWS) is a rare disorder characterized by the association of a facial birthmark called a port-wine birthmark, neurological abnormalities, and eye abnormalities such as glaucoma. SWS can be thought of as a spectrum of disease in which individuals may have abnormalities affecting all three of these systems (i.e. brain, skin and eyes), or only two, or only one. Symptoms are usually present at birth (congenital), yet the disorder is not inherited and does not run in families. Some symptoms may not develop until adulthood. SWS is caused by a somatic mutation in the GNAQ gene. This mutation occurs randomly (sporadically) for no known reason. A diagnosis of SWS is based upon identification of characteristic symptoms (e.g. port-wine birthmark), a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. A diagnosis may be straightforward in an infant with a port-wine birthmark, glaucoma, evidence of cerebral involvement and neuroimaging findings consistent with a diagnosis of SWS. Diagnosis can be more difficult in infants who have a port-wine birthmark, but no neurological symptoms. The treatment of SWS is directed toward the specific symptoms that are apparent in each individual. Laser therapy can lighten or remove the port-wine birthmark in affected individuals, even infants as young as one month old.

How is Sturge-weber Syndrome epidemiology segmented?

Sturge-weber Syndrome epidemiology is segmented as Sturge-weber Syndrome Total Incident Cases, Age-specific Sturge-weber Syndrome cases, Gender-specific Sturge-weber Syndrome Cases, Stage-specific Sturge-weber Syndrome incident cases, Type-specific Sturge-weber Syndrome incident cases, and Total Treated Sturge-weber Syndrome Cases.

What is the Sturge-weber Syndrome market size in 7MM?

The Sturge-weber Syndrome market size is expected to grow owing to the launch of emerging therapies by 2032.

At what CAGR is the Sturge-weber Syndrome Market expected to grow by 2032?

The Sturge-weber Syndrome Market is expected to grow at a moderate CAGR during the study period 2019–2032.

Which country is expected to account for the most significant Sturge-weber Syndrome prevalent cases in the 7MM?

The United States is expected to account for the highest prevalent Sturge-weber Syndrome prevalent cases.

What are the key Sturge-weber Syndrome companies?

Some of the key Sturge-weber Syndrome companies working in the Sturge-weber Syndrome market are Pfizer, Qlaris Bio, Inc., GW Pharmaceuticals, IDEAYA Biosciences, and others.

Tags:

License Type

Offer